

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>McAvoy David R.</u> _____ (Last) (First) (Middle) C/O FRESH TRACKS THERAPEUTICS, INC. 2000 CENTRAL AVENUE, SUITE 100 _____ (Street) BOULDER CO 80301 _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Fresh Tracks Therapeutics, Inc. [ FRTX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below) X Gen Counsel, CCO, & Secretary
	3. Date of Earliest Transaction (Month/Day/Year) 10/02/2023	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/02/2023		M		20,000 <sup>(1)</sup>	A	(2)	23,419 <sup>(3)(4)</sup>	D	
Common Stock	10/02/2023		F		7,358 <sup>(5)</sup>	D	\$0.9798	16,061	D	
Common Stock								310 <sup>(4)</sup>	I	By spouse

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(2)	10/02/2023		M			20,000	(6)	(6)	Common Stock	20,000	\$0	0	D	

**Explanation of Responses:**

- The restricted stock units were granted on January 24, 2023 and were subject to accelerated vesting as of the date of the reporting person's termination pursuant to his employment agreement with the issuer.
- Each restricted stock unit converted into common stock on a one-for-one basis.
- This balance includes 555 shares purchased under the Fresh Tracks Therapeutics, Inc. Employee Stock Purchase Plan that were not previously reported.
- On July 5, 2022, the registrant effected a 1-for-45 reverse stock split ("Reverse Stock Split") of its common stock. The number of shares beneficially owned has been adjusted to give effect to the Reverse Stock Split.
- Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units.
- The restricted stock units vested in full on October 2, 2023.

**Remarks:**

/s/ Christine G. Long, Attorney-in-Fact for David R. McAvoy (power 10/04/2023 of attorney previously filed)

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.